Cepheid is a molecular diagnostics leader, committed to improving healthcare with our accurate yet easy-to-use GeneXpert® system, and our expanding portfolio of Xpert® tests which span healthcare associated infections and other infectious diseases, women's health and oncology.

These Investor Relations' pages offer a wealth of information regarding Cepheid's performance to date and our strategy for the continued growth of our clinical diagnostics business. All of our SEC filings are available, in addition to our most recent quarterly announcements and corporate presentations, and a series of data sheets to help you learn about our business.

If you have questions or comments after reviewing the information available here, our Investor Relations department can be reached through the 'Contact Cepheid IR' page. Meanwhile, and on behalf of the entire team, thank you for your interest in Cepheid.

John L. Bishop
Chief Executive Officer